Loading
Runs China's national cancer centre and the registry that reports the country's cancer statistics.
Jie He is President of the Cancer Hospital of the Chinese Academy of Medical Sciences, Director of the National Cancer Center of China and a thoracic surgeon. He runs China's national cancer centre and the registry that reports the country's cancer statistics, overseeing the national cancer registry, screening programmes and clinical research infrastructure. His publications include the report on cancer incidence and mortality in China in 2022. His interests span thoracic surgery, lung and oesophageal cancer, cancer registry and statistics, and screening policy.
| Title | Journal | Year |
|---|---|---|
| Cancer incidence and mortality in China, 2022 | Journal of the National Cancer Center | 2024 |
| ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer | New England Journal of Medicine | 2020 |
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Non-small-cell lung cancer.
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Oesophageal cancer.
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Non-small-cell lung cancer.
Shares National Cancer Center of China, Non-small-cell lung cancer.
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Non-small-cell lung cancer.
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Oesophageal cancer.
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Non-small-cell lung cancer.
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Non-small-cell lung cancer.